- Retaining trial participants: an individualised approach is needed
- Human medicines European public assessment report (EPAR): Vaxneuvance, pneumococcal polysaccharide conjugate vaccine (adsorbed), Pneumococcal Infections, Date of authorisation: 13/12/2021, Status: Authorised
- Opinion/decision on a Paediatric investigation plan (PIP): Humanised recombinant IgG4, Anti-PD-1 monoclonal antibody (CS1003), decision type: , therapeutic area: , PIP number: P/0135/2021
- Agenda - COMP agenda of the 18-20 January 2022 meeting
- Opinion/decision on a Paediatric investigation plan (PIP): Anti-alpha-synuclein human monoclonal antibody, decision type: , therapeutic area: , PIP number: P/0136/2021
- Opinion/decision on a Paediatric investigation plan (PIP): sabatolimab, decision type: , therapeutic area: , PIP number: P/0164/2021
- AML digital therapeutic lands Breakthrough Device Designation from FDA
- Human medicines European public assessment report (EPAR): Ytracis, yttrium [90Y] chloride, Radionuclide Imaging, Date of authorisation: 24/03/2003, Revision: 7, Status: Withdrawn
- Opinion/decision on a Paediatric investigation plan (PIP): Anti-IL-7Rα monoclonal antibody (S95011/ OSE-127), decision type: , therapeutic area: , PIP number: P/0163/2021
- Opinion/decision on a Paediatric investigation plan (PIP): 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl) acetamide monohydrate, decision type: , therapeutic area: , PIP number: P/0137/2021
- Opinion/decision on a Paediatric investigation plan (PIP): tavapadon, decision type: , therapeutic area: , PIP number: P/0138/2021
- STAT+: Real estate developer reneges on multimillion-dollar pledge to Harvard-led Covid project
- Cidofovir : List of nationally authorised medicinal products - PSUSA/00010558/202106
- Levofloxacin/dexamethasone (ocular use) : List of nationally authorised medicinal products - PSUSA/00010881/202106
- Ofloxacin (systemic use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002203/202104
Subscribe to Regular Updates
Get insights on clinical trial transparency and regulatory changes.